Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ex-FDA chief Crawford moves into private-sector lobbying role:

This article was originally published in Clinica

Executive Summary

Former FDA commissioner Dr Lester Crawford has joined the Washington DC-based lobbying firm Policy Directions as senior counsel. Dr Crawford mysteriously resigned from his post in September only three months after Senate confirmation. He was embroiled in a controversy over whether he had politicised the agency for overruling staff and outside advisors by indefinitely postponing a decision on whether to grant Barr Laboratories' emergency contraceptive Plan B product OTC status. His sudden departure is still under investigation by the Health and Human Services department's inspector general. Policy Directions represents several food, drug and device clients, including Bausch & Lomb, Baxter Healthcare, Bayer Diagnostics, Genzyme, and Visx. To read more about lobbying, see www.healthcarelobbyist.com.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT050883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel